InvestorsHub Logo
Followers 126
Posts 15385
Boards Moderated 2
Alias Born 06/29/2006

Re: None

Wednesday, 07/03/2019 8:04:59 AM

Wednesday, July 03, 2019 8:04:59 AM

Post# of 16707
Algernon Pharmaceuticals’ NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56% Outperforming USFDA Approved Treatments Nintedanib and Pirfenidone

https://www.otcmarkets.com/stock/BTHCF/news/Algernon-Pharmaceuticals-NP-120-Reduced-Fibrosis-in-an-Idiopathic-Pulmonary-Fibrosis-Study-by-56-Outperforming-USFDA-App?id=233313